Mannitol Viaflo Baxter (Mannitol)

Mannitol works by increasing the osmolality of plasma, which draws water from cells and interstitial spaces into the blood vessels. This osmotic shift expands intravascular volume, promotes renal filtration, and reduces cerebral edema, thereby achieving diuresis and lowering intracranial pressure.

The specific dose of Mannitol Viaflo Baxter is determined by the prescribing clinician based on the patient’s condition, weight, renal function, and therapeutic goals. Dosing regimens are individualized and should follow institutional protocols and the prescriber’s orders.

Mannitol is classified as a Category C medication in many jurisdictions, meaning risk to the fetus cannot be ruled out. It should only be used during pregnancy or lactation if the potential benefit justifies the potential risk, and this decision must be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Mannitol is a non‑metabolizable sugar alcohol that exerts its effect through osmotic mechanisms, similar to agents like hypertonic saline. Compared with hypertonic saline, Mannitol provides a predictable diuretic response and is often preferred for rapid reduction of intracranial pressure, though both require careful monitoring of electrolytes and fluid balance.

Mannitol Viaflo Baxter should be stored at ambient temperature below 25 °C, protected from moisture and direct light. The vial must remain sealed until use, and any reconstituted solution should be used promptly according to the manufacturer’s instructions to maintain sterility.

Mannitol Viaflo Baxter is administered intravenously, typically as a sterile solution injected over several minutes. The infusion rate and total volume are determined by the prescriber, and the drug should be given through a dedicated IV line to avoid incompatibility with other medications.

Serious risks include acute renal failure, pulmonary edema due to fluid overload, severe electrolyte disturbances (especially hyponatremia or hyperkalemia), and rare anaphylactoid reactions. Continuous monitoring of renal function, fluid balance, and serum electrolytes is essential to detect these complications early.

Mannitol is contraindicated in patients with known hypersensitivity to mannitol, severe dehydration, active intracranial bleeding, uncontrolled heart failure, or severe renal impairment where diuresis could worsen kidney function. Clinicians should evaluate each patient’s medical history before initiating therapy.